Hznp Medicines LLC v. Actavis Laboratories UT, Inc., No. 17-2149 (Fed. Cir. Oct. 10, 2019)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

HZNP Medicines LLC and Horizon Pharma USA, Inc. (“Horizon”) appeal from the U.S. District Court for the Dis- trict of New Jersey ’s judgment of invalidity a nd nonin- fringement. Actavis Laboratories UT, Inc. (“Actavis”) cross-appeals the district court’s judgment of nonobvious- ness. We affirm. BACKGROUND Horizon1 is the assignee of U.S. Patent Nos.